Lyle Wesley Baker

Lyle Wesley Baker

Auto-generated profile, based on publicly available information

Lyle Wesley Baker

Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, Florida

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2015 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
MJMatlock A. Jeffries
Matlock A. Jeffries
MDMadison Donica
Madison Donica
LBLyle W. Baker
Lyle W. Baker
MSMichael E. Stevenson
Michael E. Stevenson
AAAnand C. Annan
Anand C. Annan
ASAmr Sawalha
Amr Sawalha
Objective: To perform a genome‐wide DNA methylation study to identify differential DNA methylation patterns in subchondral bone underlying eroded and intact cartilage from patients with hip osteoarthritis (OA) and to compare these with DNA methylation patterns in overlying cartilage.Methods: Genome‐wide DNA methylation profiling using Illumina HumanMethylation 450 arrays was performed on eroded and intact cartilage and subchondral bone from within the same joint of 12 patients undergoing hip arthroplasty. Genes with differentially methylated CpG sites were analyzed to identify shared pathways, upstream regulators, and overrepresented gene ontologies, and these patterns were compared with those of the overlying cartilage. Histopathology was graded by modified Mankin score and assessed for correlation with DNA methylation.Results: We identified 7,316 differentially methylated CpG sites in subchondral bone underlying eroded cartilage, most of which (∼75%) were hypomethylated, and 1,397 sites in overlying eroded cartilage, 126 of which were shared. Samples clustered into 3 groups with distinct histopathologic scores. We observed differential DNA methylation of genes including the RNA interference–processing gene AGO2, the growth factor TGFB3, the OA suppressor NFATC1, and the epigenetic effector HDAC4. Among known susceptibility genes in OA, 32 were differentially methylated in subchondral bone, 8 were differentially methylated in cartilage, and 5 were shared. Upstream regulator analysis using differentially methylated genes in OA subchondral bone showed a strong transforming growth factor β1 signature (P = 1 × 10−40) and a tumor necrosis factor family signature (P = 3.2 × 10−28), among others.Conclusion: Our data suggest the presence of an epigenetic phenotype associated with eroded OA subchondral bone that is similar to that of overlying eroded OA cartilage.

18 November 2021 in Case Reports in Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
LBLyle W. Baker
Lyle W. Baker
JJJaime Jimenez-Lopez
Jaime Jimenez-Lopez
XGXochiquetzal J. Geiger
Xochiquetzal J. Geiger
NANabeel Aslam
Nabeel Aslam
Membranous nephropathy (MN) is currently classified as either primary – often associated with positive anti-phospholipase-A2 receptor (PLA2R) autoantibodies – or as secondary – associated with malignancy, infection, medications, or autoimmune disease. We present a case of biopsy-proven MN with very high serum titer of anti-PLA2R autoantibodies in a patient with a synchronous diagnosis of poorly differentiated esophageal adenocarcinoma and renal cell carcinoma who presented with nephrotic syndrome. Based on the current classification, MN in the presence of active malignancy is diagnosed as secondary and unlikely to have positive anti-PLA2R autoantibodies. This raises several questions: whether this patient has secondary MN associated with malignancy and coincidentally discovered anti-PLA2R autoantibodies, primary MN due to anti-PLA2R autoantibodies with coincidentally discovered malignancy, or whether malignancy can induce the formation of anti-PLA2R autoantibodies that result in MN. This case report highlights the importance of age-appropriate cancer screening, even in patients with presumed primary MN and positive anti-PLA2R autoantibodies.

23 October 2025 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
LBLyle W. Baker
Lyle W. Baker
COCene Ovincy
Cene Ovincy
LSLevon Souvalian
Levon Souvalian
LHLaTonya J. Hickson
LaTonya J. Hickson
FCFouad Chebib
Fouad Chebib

18 February 2021 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
LBLyle Wesley Baker
Lyle Wesley Baker
MKMahnoor Khan
Mahnoor Khan
CCCherise Cortese
Cherise Cortese
NANabeel Aslam
Nabeel Aslam
Fibrillary glomerulonephritis (FGN) and complement 3 glomerulopathy (C3G) are rare forms of glomerulonephritis with distinct aetiologies. Both FGN and C3G can present with nephritic syndrome. FGN is associated with autoimmune disease, dysproteinaemia, malignancy and hepatitis C infection. C3G is caused by the unregulated activation of the alternative complement pathway. We present a rare case of diffuse necrotising crescentic glomerulonephritis with dominant C3 glomerular staining on immunofluorescence—consistent with C3G—but electron microscopy (EM) findings of randomly oriented fibrils with a mean diameter of 14 nm and positive immunohistochemistry for DNAJB9—suggestive of FGN. To the best of our knowledge, this is the first reported case of FGN to show dominant C3 glomerular deposits. This case report reaffirms the utility of EM in the evaluation of nephritic syndrome and highlights the value of DNAJB9—a novel biomarker with a sensitivity and specificity near 100% for FGN.

16 May 2025 in Kidney Medicine
Verified
Journal Article
Open access
LBLyle W. Baker
Lyle W. Baker
TJTambi Jarmi
Tambi Jarmi
MMMichael A. Mao
Michael A. Mao
IPIvan E. Porter
Ivan E. Porter
CTChristopher L. Trautman
Christopher L. Trautman
NANabeel Aslam
Nabeel Aslam
Ventricular assist devices (VADs) are used for advanced heart failure, but their impact on kidney function remains unclear. This study evaluated changes in kidney function following VAD implantation, including acute kidney injury (AKI) incidence and need for kidney replacement therapy (KRT). A retrospective cohort study analyzing longitudinal kidney function outcomes post-VAD placement. Adult patients who underwent durable VAD placement (2009-2019) at a single center were included. Patients were stratified into chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73m2) and non-CKD (eGFR ≥60 mL/min/1.73m2) groups. The VAD implantation was the primary intervention, with baseline kidney function modifying its impact on post-VAD kidney function. Primary outcomes were changes in eGFR and creatinine at 3-months and 12-months post-VAD. Secondary outcomes included AKI incidence, KRT requirement, and postdischarge AKI within 1 year. Descriptive statistics and comparative analyses, including Wilcoxon rank sum, χ2, and paired t tests, were used to assess differences. Significance was set at P < 0.05. Among 160 patients (82% male and 69% White), patients with CKD were older with a higher prevalence of diabetes, vasodilator use, and inotrope use. At 3 months, kidney function improved in patients with CKD (eGFR +17, P < 0.001) but declined by 12 months (eGFR +7, P = 0.03). The non-CKD group had a smaller improvement at 3 months (eGFR +8, P = 0.004) that was not sustained. AKI requiring KRT occurred in 14%, with 45% in-hospital mortality; and 41% discontinued KRT before discharge. Post-VAD AKI occurred in 21%. Half of the patients underwent heart transplant, which was associated with worsening kidney function at 1-year. Single-center design limits generalizability. The VAD placement initially improves kidney function, particularly in CKD patients, but this effect diminishes over time. AKI and KRT use are common, highlighting the need for close kidney monitoring post-VAD.

7 July 2025 in Kidney360
Verified
Journal Article
Open access
FDFadi George Munairdjy Debeh
Fadi George Munairdjy Debeh
AGAhmad Ghanem
Ahmad Ghanem
VRVineetha Rangarajan
Vineetha Rangarajan
ABAbdul Hamid Borghol
Abdul Hamid Borghol
SPStefan Paul
Stefan Paul
NANabeel Aslam
Nabeel Aslam
Key Points: This study demonstrates that peritoneal dialysis is a safe and feasible option for patients with autosomal dominant polycystic kidney disease, even with high cystic organ volumes. Larger organ volumes, including height-adjusted cumulative kidney and liver volume, were not associated with increased peritoneal dialysis–related complications. Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disorder and the fourth leading cause of kidney failure. Peritoneal dialysis (PD), preferred for its home-based convenience and cost-effectiveness, is often underutilized in ADPKD because of concerns over enlarged kidneys and heightened risk of complications. Methods: This retrospective cohort study used data from the Mayo Clinic Polycystic Kidney Disease Database to evaluate individuals with ADPKD undergoing PD. We analyzed demographics, clinical parameters, and PD-related parameters. Complications were correlated with kidney and liver volumes derived from pre-kidney failure imaging. Results: A total of 155 individuals with ADPKD on PD were included, of whom 45.1% were male. The mean age at PD initiation was 54.3±12.8 years, and the mean body mass index was 28.0±7.0 kg/m 2 . The median duration of PD was 24.3 months (interquartile range [IQR], 10.7–43.1), with 21.9% transitioning to hemodialysis. The most common complications were abdominal hernias (30.3%) and peritonitis (23.9%), with a peritonitis rate of 0.11 episodes per patient-year. Imaging analyses performed on a subset of 50 patients showed a median height-adjusted total kidney liver volume of 2731.9 ml/m (IQR, 2102.5–3131.1) and a median height-adjusted total kidney volume of 1303.5 ml/m (IQR, 733.1–1829.4). Kaplan–Meier analysis demonstrated no differences in complications rates on the basis of height-adjusted total kidney liver volume or height-adjusted total kidney volume (above versus below median values) or body mass index categories. Multivariate Cox regression analysis revealed that higher height-adjusted cumulative organ volume was associated with a lower risk of PD-related complications (hazard ratio=0.56, P = 0.026). Conclusions: PD is a safe and feasible treatment option for patients with ADPKD, with no increased risk of PD-related complications associated with larger height-adjusted cumulative organ volumes. Infectious complication rates in this cohort were within International Society of Peritoneal Dialysis guideline thresholds, further supporting the safety of PD in this population.